About Servier
Servier is an independent international pharmaceutical group governed by a foundation. With its unique governance model, the Group is committed to therapeutic progress to serve patients and integrates the patient voice at every stage of the medicine life cycle.
As a leading global player in cardiology and venous diseases1, Servier aims to become a leading innovator in oncology and neurology. Through precision medicine, the Group intends to offer targeted therapeutic solutions for a limited number of rare diseases and invests nearly 20% of its brand-name sales in R&D.
Headquartered in France, Servier relies on its more than 20,000 employees and a solid geographic presence with medicines distributed in more than 130 countries.
“Servier” has been operating in Russia for nearly 35 years. It is one of the leading pharmaceutical companies. In 2007, the high-tech manufacturing complex “Servier RUS” was launched in New Moscow. It operates in full compliance with the requirements of the international Good Manufacturing Practice (GMP) standard and produces a wide range of modern, brand-name medications for the treatment of major chronic diseases for patients in Russia and EAEU countries. Today, more than 90% of Servier’s branded medicines in Russia are manufactured through a full production cycle at the pharmaceutical plant in Moscow.
Additional information: www.servier.ru
__________________________
1IQVIA, Analytics Link / World 84 countries – MAT Q3-2025.